Infusion Therapies

Sublocade

Sublocade is a form of infusion therapy used to treat opioid use disorder by providing a monthly extended-release injection to help prevent opioid dependence.

Vivitrol

Vivitrol is another infusion therapy option that aids in the treatment of alcohol dependence and opioid use disorder by blocking certain receptors in the brain to reduce cravings and the pleasurable effects of opioids and alcohol.

Cinqair

Cinqair is a medication administered through infusion to treat severe asthma.

Cinryze

Cinryze is an infusion therapy for the prevention of hereditary angioedema attacks.

Fasenra

Fasenra is used as an infusion to manage severe eosinophilic asthma.

Nucala

Nucala is administered as an infusion to control severe asthma symptoms.

Tezspire

Tezspire is an infusion treatment option for certain respiratory conditions.

Xolair

Xolair is given through infusion for the management of allergic asthma and chronic idiopathic urticaria.

Leqvio

Leqvio is a medication that is administered through infusion for the treatment of high cholesterol levels in patients with familial hypercholesterolemia (FH). It works by targeting a specific protein in the liver, called PCSK9, which helps to reduce the amount of "bad" cholesterol in the blood. By blocking this protein, Leqvio can help lower cholesterol levels and decrease the risk of heart disease.

Cosentyx

Cosentyx is a medication used to treat conditions like psoriasis or psoriatic arthritis by targeting specific proteins in the body.

Ilumya

Ilumya is an infusion prescribed for treating moderate to severe plaque psoriasis in adults by blocking certain proteins that cause inflammation.

Remicade

Remicade is a biologic drug used for various autoimmune diseases, including psoriatic arthritis.

Spevigo

Spevigo is an infusion used for treating moderate to severe plaque psoriasis in adults by targeting specific proteins that contribute to inflammation. It works by blocking the activity of these proteins, helping to improve symptoms and reduce the severity of the condition.

Stelara

Stelara is an infusion treatment for conditions such as psoriasis and psoriatic arthritis that works by inhibiting specific proteins in the immune system.

Crysvita

Crysvita is an infusion used for the treatment of rare endocrine disorders, such as X-linked hypophosphatemia (XLH). It works by binding to and blocking a protein that regulates phosphate levels in the body, helping to increase the amount of phosphate available for bone growth and maintenance. This can help improve symptoms such as bone pain and weakness in patients with XLH.

Evenity

Evenity is an infusion treatment for patients with osteoporosis, a condition in which bones become weak and brittle. It works by inhibiting a protein called sclerostin, which helps to regulate the formation and breakdown of bone tissue. By blocking this protein, Evenity can help increase bone density and reduce the risk of fractures in patients with osteoporosis.

Injectafer

Injectafer is an iron replacement therapy used to treat iron deficiency anemia, a condition in which the body does not have enough healthy red blood cells due to low levels of iron. Injectafer works by delivering iron directly into the bloodstream through intravenous infusion, helping to replenish iron stores and increase the production of red blood cells. It is often prescribed for patients who are unable to take oral iron supplements or do not respond well to them.

Prolia

Prolia is a medication used to treat osteoporosis and prevent bone fractures. It works by inhibiting the activity of osteoclasts, cells responsible for breaking down bone tissue. By reducing the number and activity of these cells, Prolia helps to increase bone density and strength. It is typically given as an injection every six months and has been shown to significantly reduce the risk of fractures in postmenopausal women with osteoporosis.

Rituxan

Rituxan is a biologic medication used to treat certain types of cancer and autoimmune diseases. It works by targeting and binding to specific proteins on the surface of B cells, which are immune cells that can contribute to the development of these conditions. By binding to these proteins, Rituxan helps to decrease the number of B cells in the body and reduce inflammation. It is typically given as an intravenous infusion every few weeks, depending on the condition being treated.

Ruxience

Ruxience is a biosimilar medication to Rituxan that has recently been approved by the FDA. Biosimilars are medications that are highly similar to existing biologic drugs, but may have minor differences due to the manufacturing process. Ruxience works in the same way as Rituxan, targeting and binding to specific proteins on B cells, but it is typically given as an injection instead of an infusion.

Tepezza

Tepezza is a medication used to treat thyroid eye disease, a condition where the muscles and tissue behind the eyes become inflamed, causing bulging eyes and vision problems. It works by targeting specific proteins in the body that contribute to this inflammation, helping to reduce swelling and improve symptoms. Tepezza is typically given as an infusion every three weeks for eight total treatments.

Truxima

Truxima is another biosimilar medication, similar to Rituxan and Ruxience, used to treat certain types of cancer and autoimmune disorders. Like its counterparts, it works by targeting specific proteins on cells that contribute to disease processes. However, Truxima may have slight differences in its structure compared to the original biologic drug, but still has been proven to be just as effective in clinical trials.

Venofer

Venofer is an iron replacement medication used to treat iron deficiency anemia. It works by replenishing the body's supply of iron, which is essential for red blood cell production. Venofer is typically given as an infusion and can improve symptoms such as fatigue and weakness in those with low iron levels.

Thyrotropin

Thyrotropin alfa is a synthetic form of the hormone thyrotropin, which is responsible for regulating thyroid function. It is used in the treatment of hypothyroidism and certain types of thyroid cancer. Thyrotropin alfa works by stimulating the production of thyroid hormones, helping to restore normal levels in the body.

Avsola

Avsola (infliximab-axxq) is a biologic therapy used to treat moderately to severely active ulcerative colitis and Crohn's disease in adults, as well as reducing signs and symptoms and maintaining clinical remission in pediatric patients 6 years of age and older. It is administered through intravenous infusion and may cause side effects such as infusion reactions and stomach pain.

Entyvio

Entyvio (vedolizumab) is indicated for the treatment of ulcerative colitis and Crohn's disease in adult patients. It works by specifically targeting the gut, and it is administered via intravenous infusion. Side effects may include headache, joint pain, and abdominal pain.

Feraheme

Feraheme (ferumoxytol) is an intravenous iron replacement therapy used to treat iron deficiency anemia in adult patients with chronic kidney disease. It is administered as a rapid intravenous injection and may cause serious hypersensitivity reactions.

Givlaari

Givlaari (givosiran) is a prescription medicine used to treat acute hepatic porphyria, a rare genetic disorder affecting the liver. It is given as a subcutaneous injection once monthly and may lead to injection site reactions and nausea.

Inflectra

Inflectra (infliximab-dyyb) is a biosimilar to Remicade and is used to treat various autoimmune diseases, including Crohn's disease, ulcerative colitis, rheumatoid arthritis, and ankylosing spondylitis. It is administered via intravenous infusion and may cause infusion reactions and increased risk of infections.

Injectafer

Injectafer (ferric carboxymaltose) is an iron replacement product used to treat iron deficiency anemia in adult patients who have intolerance to oral iron or have had an unsatisfactory response to oral iron. It is administered by intravenous injection and may cause hypophosphatemia and hypersensitivity reactions.

Omvoh

Omvoh (vesatolimod) is a prescription medicine used for the treatment of chronic hepatitis B virus infection. It is administered subcutaneously and may cause injection site reactions and flu-like symptoms.

Remicade

Remicade (infliximab) is used to treat a variety of inflammatory conditions, including rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriatic arthritis, and ankylosing spondylitis. It is given as an intravenous infusion and may lead to infusion reactions, increased risk of infections, and malignancies.

Renflexis

Renflexis (infliximab-abda) is a biosimilar to Remicade and is used to treat several autoimmune diseases, including Crohn's disease, ulcerative colitis, rheumatoid arthritis, and ankylosing spondylitis. It is administered via intravenous infusion and may cause infusion reactions and increased risk of infections.

Skyrizi

Skyrizi (risankizumab) is used to treat moderate to severe plaque psoriasis by inhibiting the interleukin-23 pathway. It is administered via subcutaneous injection and may cause upper respiratory infections and headache.

Stelara

Stelara (ustekinumab) is indicated for the treatment of plaque psoriasis, psoriatic arthritis, and Crohn's disease. It is administered as a subcutaneous injection and may lead to upper respiratory infections, headache, and fatigue.

Venofer

Venofer (iron sucrose) is an iron replacement product used to treat iron deficiency anemia in adult patients with chronic kidney disease. It is administered by intravenous injection and may cause hypotension and hypersensitivity reactions.

Fasenra

Fasenra (benralizumab) is a monoclonal antibody used as an add-on maintenance treatment for patients aged 12 and older with severe eosinophilic asthma. It works by reducing the level of a specific type of white blood cells.

Nucala

Nucala (mepolizumab) is indicated for the add-on maintenance treatment of severe eosinophilic asthma in patients aged 6 years and older. It is also used to treat eosinophilic granulomatosis with polyangiitis (EGPA) in adults.

Ultomiris

Ultomiris (ravulizumab-cwvz) is a long-acting C5 complement inhibitor used for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in adult patients. It is also indicated for the treatment of atypical hemolytic uremic syndrome (aHUS) in adult and pediatric patients.

Xolair

Xolair (omalizumab) is used to treat moderate to severe persistent allergic asthma and chronic idiopathic urticaria (CIU) in patients aged 12 years and older. It works by targeting and blocking immunoglobulin E (IgE).

Feraheme

Feraheme (ferumoxytol) is an intravenous iron replacement product used to treat iron deficiency anemia in adults who have intolerance to oral iron or have had an unsatisfactory response to oral iron.

Injectafer

Injectafer (ferric carboxymaltose) is indicated for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had an unsatisfactory response to oral iron.

Venofer

Venofer (iron sucrose) is used to treat iron deficiency anemia in patients with chronic kidney disease.

Gammagard

Gammagard is an intravenous immunoglobulin (IVIG) therapy used to strengthen the body's natural defense system in individuals with primary immunodeficiency, autoimmune diseases, multifocal motor neuropathy, and Alzheimer's disease.

Gammaked

Gammaked, similar to Gammagard, is an IVIG solution utilized by healthcare professionals to treat primary immune deficiency and to reduce the susceptibility to infections in individuals with compromised immune systems.

Gammunex-C

Gammunex-C is an IVIG therapy indicated for the treatment of primary immunodeficiency and certain autoimmune diseases. It is administered intravenously and works to bolster the body's immune response, reducing the risk of infections in susceptible individuals.

Octagam

Octagam is an intravenous immunoglobulin therapy used to boost the immune system's defenses in patients with primary immunodeficiency and autoimmune conditions. It is administered through intravenous infusion and is aimed at lowering the risk of infections in individuals with compromised immunity.

Evenity

Evenity (romosozumab-aqqg) is known for its crucial role in treating osteoporosis in postmenopausal women who are at high risk of fractures. While it is not directly linked to nephrology, the management of bone health in postmenopausal women, including those with chronic kidney disease, is a significant concern within nephrology.

Injectafer

Injectafer (ferric carboxymaltose) is often utilized in the nephrology field for the management of iron deficiency anemia in adult patients with chronic kidney disease who are undergoing dialysis. Iron deficiency is a common concern in individuals with kidney disease, and products like Injectafer play a role in addressing this issue.

Krystexxa

Krystexxa (pegloticase) is not directly associated with nephrology applications, as its primary indication is for the treatment of chronic gout. However, chronic gout and hyperuricemia are conditions that can have implications for kidney function, as urate crystal deposition in the kidneys can lead to kidney stones and other complications.

Nulojix

Nulojix (belatacept) is used as an immunosuppressive medication in adult kidney transplant patients to prevent organ rejection after a kidney transplant. Transplant immunosuppression and the management of post-transplant care are integral parts of nephrology practice, as they directly influence the success of kidney transplants and long-term patient outcomes.

Oxlumo

Oxlumo (lumasiran) is employed in the treatment of primary hyperoxaluria type 1 (PH1) in both adults and pediatric patients. PH1 is a rare genetic disorder that can lead to kidney stone formation and progressive kidney damage.

Prolia

Prolia (denosumab) plays a role in the management of osteoporosis in postmenopausal women and in increasing bone mass in men with osteoporosis. Managing bone health and reducing the risk of fractures in this patient population is an important aspect of nephrology care, and medications like Prolia may be considered as part of a comprehensive approach to addressing bone complications in individuals with renal issues.

Aduhelm

Aduhelm, also known as aducanumab-avwa, was the first treatment to reduce amyloid plaques in the brains of people with Alzheimer's disease. However, it is important to note that the manufacturer, Biogen, has decided to discontinue this treatment in 2024, shifting resources to other Alzheimer's medications such as LEQEMBI® (lecanemab-irmb) and developing new treatments.

Algucosidase Alfa

Algucosidase alfa is an enzyme replacement therapy used for the treatment of Pompe disease, a rare genetic disorder characterized by the buildup of glycogen in certain organs and tissues, including the muscles. This medication addresses the neurological manifestations of Pompe disease by targeting the underlying enzyme deficiency and associated symptoms.

Alglucosidase Alfa-NGP

Alglucosidase alfa-NGP is another form of enzyme replacement therapy utilized for the treatment of Pompe disease, similarly addressing the neurological aspects of this rare genetic disorder by targeting the enzyme deficiency responsible for the condition.

Amvuttra

Amvuttra is a medication used in the treatment of migraine headaches, a neurological condition characterized by recurrent episodes of moderate to severe headaches. As migraine management falls within the purview of neurology, medications like Amvuttra play a role in addressing the specific needs of individuals suffering from migraines.

Briumvi

Briumvi is a prescription medicine used for the preventive treatment of migraine in adults, making it relevant within the field of neurology due to its application in addressing migraine, a neurological disorder.

Cabenuva

Cabenuva, indicated for the treatment of HIV-1 infection in adults, serves as a relevant medication within neurology due to the potential neurological implications of HIV infection. Managing HIV-associated neurological complications is an important aspect of comprehensive neurology care, highlighting the significance of medications like Cabenuva in this context.

Feraheme

Feraheme is an iron replacement therapy used to treat iron deficiency anemia in adult patients with chronic kidney disease. While not directly targeting neurological conditions, iron deficiency anemia can lead to cognitive impairment, making therapies like Feraheme indirectly relevant to neurological considerations.

Leqembi

LEQEMBI® (lecanemab-irmb) is an Alzheimer's medication developed by Biogen, representing a significant focus within neurology given its involvement in addressing the underlying pathology of Alzheimer's disease.

Migraine

Migraine is a neurological condition characterized by recurrent moderate to severe headaches, often accompanied by other symptoms such as nausea and sensitivity to light. Treatments for migraine, including preventive medications and acute relief options, are central to the management of this neurological disorder.

Ocrevus

Ocrevus is a medication used in the treatment of multiple sclerosis, a chronic inflammatory disease of the central nervous system. Its role in managing the progression of this neurological condition highlights its significance within the field of neurology.

Onpattro

Onpattro is utilized in the treatment of polyneuropathy in people with hereditary transthyretin-mediated amyloidosis (hATTR). This demonstrates its relevance within the neurological landscape by addressing specific neuropathic manifestations associated with this genetic disorder.

Oxlumo

Oxlumo, or lumasiran, is employed in the treatment of primary hyperoxaluria type 1, a rare genetic disorder characterized by the overproduction of oxalate, potentially leading to kidney and neurological complications. Its application in mitigating the neurological impact of this condition underscores its significance within the realm of neurology.

Qutenza

Qutenza is a topical medication used in the management of neuropathic pain associated with postherpetic neuralgia, a type of nerve pain occurring after a shingles infection. Its relevance to neurology lies in its role in addressing specific neuropathic pain syndromes.

Radicava

Radicava, or edaravone, is used in the treatment of amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease affecting nerve cells in the brain and spinal cord. Its utilization in combating the progression of ALS underscores its importance within the neurology field.

Rituxan, Rituximab

Rituxan, also known as rituximab, is utilized in the treatment of certain autoimmune disorders that can have neurological implications, such as neuromyelitis optica spectrum disorder and certain types of vasculitis, highlighting its relevance within neurology.

Soliris

Soliris, or eculizumab, is employed in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease with neurological manifestations. Its application in targeting the underlying immune mechanisms of NMOSD emphasizes its significance within neurology.

Evenity

Evenity, also known as romosozumab-aqqg, is a medication used to treat osteoporosis in postmenopausal women at high risk for fracture. It works by increasing new bone formation and is specifically indicated for women who have been through menopause and have a history of osteoporotic fracture.

Prolia

Prolia, with the active ingredient denosumab, is prescribed to treat osteoporosis in postmenopausal women, as well as in men with a high risk of fracture. It works by inhibiting bone resorption and has been proven effective in reducing the risk of fractures in patients with osteoporosis.

Tepezza

Tepezza, or teprotumumab-trbw, is administered through a series of 8 infusions, with each infusion given once every 3 weeks. This treatment regimen spans about 5 months and is designed to reduce eye bulging, double vision, and other symptoms associated with Thyroid Eye Disease (TED). The medication has shown efficacy in improving the signs and symptoms of TED, such as eye pain, redness, and swelling.

Uplizna

Uplizna, known by the generic name inebilizumab-cdon, is utilized as an infusion therapy for the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease affecting the optic nerves and spinal cord. It works by targeting specific B cells involved in the immune response, thereby reducing the risk of NMOSD relapses.

Aralast

Aralast, also known as ARALAST® NP, is an infusion therapy designed to treat adults with lung disease caused by severe Alpha1 antitrypsin (AAT) deficiency. It is administered once weekly by intravenous infusion and is indicated for chronic augmentation therapy in individuals with clinically evident emphysema due to severe AAT deficiency.

Cerezyme

Cerezyme, with the active ingredient imiglucerase, is utilized as an enzyme replacement therapy for patients with Type 1 Gaucher disease. This infusion therapy aims to alleviate symptoms associated with the condition, such as anemia, thrombocytopenia, bone disease, and hepatosplenomegaly.

Glassia

Glassia, an Alpha1-Proteinase Inhibitor (Human), is an infusion therapy indicated for chronic augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 antitrypsin deficiency. It is administered intravenously and works to increase the levels of AAT, a protein that helps protect the lungs from damage caused by inflammation.

Proclastin-C (Prolastin)

Proclastin-C, also known as Prolastin, is a medication made from human Alpha1-Proteinase Inhibitor (A1-PI) and is used for augmentation and maintenance therapy in individuals with emphysema due to A1-PI deficiency. It is administered intravenously and aims to restore levels of A1-PI to protect the lungs from damage caused by A1-PI deficiency.

Tezspire

Tezspire is an infusion therapy indicated for the treatment of hereditary angioedema (HAE) in patients 12 years of age and older. It functions by increasing plasma levels of C1 esterase inhibitor (C1-INH) and is administered at regular intervals to help prevent HAE attacks.

Xolair

Xolair, or omalizumab, is prescribed as an infusion therapy for allergic asthma and chronic idiopathic urticaria. It works by targeting and inhibiting IgE antibodies involved in allergic responses, thus helping to alleviate asthma symptoms and chronic hives.

Actemra

Actemra, also known as tocilizumab, is a prescription medicine classified as an interleukin-6 (IL-6) receptor antagonist. It is indicated for the treatment of various conditions, including rheumatoid arthritis (RA), giant cell arteritis (GCA), systemic juvenile idiopathic arthritis (SJIA), polyarticular juvenile idiopathic arthritis (PJIA), and it has also been used in the treatment of COVID-19.

Avsola

Avsola, or infliximab-axxq, is a biosimilar to Remicade and is used to treat various autoimmune conditions, including rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.

Benlysta

Benlysta, with the active ingredient belimumab, is a biologic infusion therapy approved for the treatment of systemic lupus erythematosus (SLE) in adults and children aged 5 years and older.

Cimzia

Cimzia, or certolizumab pegol, is an injectable medication used to treat various inflammatory conditions, such as rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, and Crohn's disease.

Crysvita

Crysvita, known as burosumab, is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients. It is administered as a subcutaneous injection.

Cosentyx

Cosentyx, or secukinumab, is an injection therapy used to treat conditions such as moderate to severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis.

Evenity

Evenity, or romosozumab, is prescribed for the treatment of osteoporosis in postmenopausal women at high risk for fracture. It helps increase new bone formation and reduce the risk of fractures.

Illaris

Illaris, canakinumab, is indicated for the treatment of several autoinflammatory conditions, including periodic fever syndromes, familial Mediterranean fever, tumor necrosis factor receptor-associated periodic syndrome, and hyperimmunoglobulin D syndrome/mevalonate kinase deficiency.

Inflectra

Inflectra, or infliximab-dyyb, is a biosimilar to Remicade and is utilized to treat various autoimmune conditions, including rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.

Krystexxa

Krystexxa, pegloticase, is indicated for the treatment of chronic gout in adults who have not responded to standard gout treatment. It is administered through intravenous infusion.

Orencia

Orencia, or abatacept, is a medication used to treat rheumatoid arthritis, juvenile idiopathic arthritis, and psoriatic arthritis. It works by inhibiting T-cell activation.

Prolia

Prolia, denosumab, is prescribed for the treatment of osteoporosis in postmenopausal women and men at high risk of fracture. It inhibits bone resorption, reducing the risk of fractures in osteoporosis patients.

Remicade

Remicade, infliximab, is used to treat a variety of autoimmune conditions, including rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.

Renflexis

Renflexis, infliximab-abda, is a biosimilar to Remicade and is utilized to treat various autoimmune conditions, including rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.

Rituxan

Rituxan, rituximab, is a biologic therapy used to treat certain types of non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis.

Ruxience

Ruxience, rituximab-pvvr, is a biosimilar to Rituxan and is used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis.

Saphnelo

Saphnelo, anifrolumab-fnia, is indicated for the treatment of systemic lupus erythematosus (SLE) in adults. It works as an interferon inhibitor, decreasing inflammation and reducing the severity of SLE symptoms such as joint pain, fatigue, and skin rashes.

Simponi Aria

Simponi Aria, with the active ingredient golimumab, is a tumor necrosis factor (TNF) blocker indicated for the treatment of conditions such as moderately to severely active rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. It is administered through intravenous infusion and works to reduce signs and symptoms of these inflammatory diseases.

Stelara

Stelara, also known as ustekinumab, is a biologic infusion therapy used to treat conditions such as moderate to severe plaque psoriasis, psoriatic arthritis, and moderately to severely active Crohn's disease. It works by targeting specific proteins in the body’s immune system that are believed to cause inflammation.

Truxima

Truxima, or rituximab-abbs, is a biosimilar to Rituxan and is used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis. It is an infusion medication that targets specific cells in the immune system.